About Harbin Medisan Pharmaceutical Company

The company is a listed pharmaceutical company with multiple varieties and multiple dosage forms for domestic and foreign markets, and is a high-tech enterprise. The company was founded in 1996. In 2001, freeze-dried powders, small-volume injections, and large-volume injections passed the national GMP certification at one time. The company's production capacity was rapidly improved, and economic efficiency improved rapidly. Since 2011, the company has sought prosperity and development based on group chemical operations, officially established the Kazakh Sanlian Pharmaceutical Research Institute, completed the shareholding system reform in 2013, and successfully listed on the Shenzhen Stock Exchange on September 22, 2017. It is mainly engaged in R&D, production and sales of chemical preparations and specialty raw materials. The main products are mirtazapine tablets, olacetam injections, piracetam injections, olacetam sodium chloride injections, edaravone injections, betastine hydrochloride injections, ligustrazine hydrochloride injections for injections, esprolol hydrochloride for injections, injectable brain protein hydrolysates (III), pentoxifylline injections, valsartan dispersible tablets, sarcosinopeptide for injections, sodium ferulinate for injections, osteopeptides for injections, loxicam for injections, sodium osteopeptide chloride injections Nin, itraconazole dispersible tablets, rifamycin sodium for injection, clindamycin phosphate injections, metronidazole glucose injections, Tinidazole sodium chloride injection, levofloxacin sodium chloride injection, sodium chloride injection, glucose injection, alanyl glutamine injection, etc. Corporate honors: Sodium Ferulate for cardiovascular injections was awarded the first prize for scientific and technological progress in the pharmaceutical industry in Heilongjiang Province; the company paid taxes in good faith and made outstanding contributions, and was included in the “National Qianhu Group Headquarters Enterprise” by the State Administration of Taxation; deepening its brand development strategy, Harbin Sanlian was awarded the honorary titles of “2018 China's Top 20 Companies with Brand Value of 100 Million Yuan”; in the first half of 2019, with R&D innovation and professional promotion advantages, Harbin Sanlian was awarded the honorary titles of “2018 China's Top 100 Chemical Companies” 64th place, Top 50 private enterprises in Harbin in 2023, national intellectual property demonstration enterprises in 2022.